

**Summary of Consolidated Financial Results [IFRS]
for the First Nine Months of the Fiscal Year Ending March 31, 2026**

February 12, 2026

Listed company name	:	Sysmex Corporation
Code	:	6869
Listed stock exchanges	:	Tokyo Stock Exchange
URL	:	www.sysmex.co.jp/en
Company representative	:	Kaoru Asano, President
Contact	:	Takuro Minami, Executive Vice President of Corporate Business Administration
Phone	:	078(265)-0500
Scheduled date for dividend payment	:	—
Preparation of supplementary material for quarterly earnings	:	Yes
Holding of earnings announcement	:	Yes

(Unit: Millions of Yen)

1. Results for the First Nine Months of the Fiscal Year Ending March 31, 2026

(1) Operating results

(% changes as compared with the corresponding period of the previous fiscal year)

	Net Sales		Operating profit		Profit before tax		Profit	
Nine months ended Dec. 31, 2025	361,168	(1.6)%	48,657	(27.7)%	47,471	(23.2)%	33,522	(21.1)%
Nine months ended Dec. 31, 2024	366,866	12.4%	67,345	24.2%	61,792	20.9%	42,497	23.2%

	Profit attributable to owners of the parent		Total comprehensive income		Basic earnings per share (Yen)	Diluted earnings per share (Yen)
Nine months ended Dec. 31, 2025	33,694	(20.9)%	60,121	23.7%	54.05	54.05
Nine months ended Dec. 31, 2024	42,615	23.7%	48,586	1.9%	68.35	68.33

(2) Financial condition

	Total assets	Total equity	Equity attributable to owners of the parent	Equity attributable to owners of the parent to total assets
As of Dec. 31, 2025	698,249	501,429	500,842	71.7%
As of Mar. 31, 2025	665,268	464,534	463,776	69.7%

2. Dividend

	Dividend per share				
	First quarter (Yen)	Second quarter (Yen)	Third quarter (Yen)	Year-end (Yen)	Annual (Yen)
Year ended Mar. 31, 2025	—	15.00	—	17.00	32.00
Year ending Mar. 31, 2026	—	19.00	—		
Year ending Mar. 31, 2026 (Forecast)				19.00	38.00

Notes: 1. Revision of dividends forecast for this period: No

2. Details of the dividends for the fiscal year ending March 31, 2026

Second quarter	Ordinary dividend: ¥18.00
	Commemorative dividend: ¥1.00 (30th anniversary of listing)
Year-end	Ordinary dividend: ¥18.00
	Commemorative dividend: ¥1.00 (30th anniversary of listing)

3. Financial Forecast for the Year Ending March 31, 2026

(% changes as compared with the previous fiscal year)

	Net Sales		Operating profit		Profit before tax		Profit attributable to owners of the parent		Basic earnings per share (Yen)
Year ending Mar. 31, 2026	500,000	(1.7)%	62,000	(29.2)%	59,000	(25.5)%	41,000	(23.6)%	65.77

Note: Revision of financial forecast for this period: Yes

4. Other Information

- (1) Significant changes in scope of consolidation: No
- (2) Changes in accounting policies and accounting estimates
 - 1) Changes in accounting policies required by IFRS: No
 - 2) Other changes in accounting policies: No
 - 3) Changes in accounting estimates: No
- (3) Number of outstanding stock (common stock)
 - 1) Number of outstanding stock at the end of each fiscal period (including treasury stock):
629,480,076 shares as of Dec. 31, 2025; 629,473,176 shares as of Mar. 31, 2025
 - 2) Number of treasury stock at the end of each fiscal period:
6,300,045 shares as of Dec. 31, 2025; 5,873,371 shares as of Mar. 31, 2025
 - 3) Average number of outstanding stock for each period (cumulative):
623,393,669 shares for the nine months ended Dec. 31, 2025
623,514,070 shares for the nine months ended Dec. 31, 2024

Note: The Company has introduced Executive Compensation BIP Trust and Stock-Granting Employee Stock Ownership Plan (ESOP) Trust. Company shares held by the trust are included in treasury stock and are excluded from calculations of the number of treasury stock at the end of the fiscal period and the average number of outstanding stock for the period.

* Review of the accompanying quarterly consolidated financial statements by a certified public accountant or auditing firm: Yes (optional)

* Explanation regarding the appropriate use of financial forecast and other information

1. The forecasts and future projections contained herein have been prepared on the basis of rational decisions given the information available as of the date of announcement of this document. These forecasts do not represent a commitment by the Company, and actual performance may differ substantially from forecasts for a variety of reasons. Please refer to "3) Consolidated financial forecast" within "1. Qualitative information on quarterly financial results" on page 4 of the attachment to this document for cautionary statements concerning the conditions and performance forecasts that serve as the basis for these forecasts.
2. Supplementary financial materials (in Japanese and English) will be posted on the Sysmex website on Thursday, February 12, 2026.

Content of Supplementary Materials

1. Qualitative information on quarterly financial results	2
1) Operating performance analysis	2
2) Financial conditions analysis	3
3) Consolidated financial forecast	4
4) Operating risks	4
5) Business and financial issues to be addressed	4
6) Important management contracts, etc.	4
2. Condensed quarterly consolidated financial statements and notes	5
1) Condensed quarterly consolidated statement of financial position	5
2) Condensed quarterly consolidated statement of income	7
3) Condensed quarterly consolidated statement of comprehensive income	8
4) Condensed quarterly consolidated statement of changes in equity	9
5) Condensed quarterly consolidated statement of cash flows	10
6) Notes to the condensed quarterly consolidated financial statements	11
1. Key considerations on the basis for the preparation of condensed quarterly consolidated financial statements	11
2. Notes related to the going concern assumption	11
3. Segment information	11

1. Qualitative information on quarterly financial results

Future-related information contained in the text below is based on the Company's judgement as of the end of the fiscal period under review.

1) Operating performance analysis

The Group's consolidated financial results for the first nine months of the fiscal year ending March 31, 2026 are as follows.

Net sales by destination

	Nine months ended December 31, 2024		Nine months ended December 31, 2025		YoY (Previous period = 100)
	Amount (Millions of yen)	Percentage of total (%)	Amount (Millions of yen)	Percentage of total (%)	
Japan	47,190	12.9	40,509	11.2	85.8
Americas	96,425	26.3	100,829	27.9	104.6
EMEA (Europe, the Middle East, and Africa)	102,871	28.0	114,909	31.8	111.7
China	82,000	22.3	65,533	18.2	79.9
AP (Asia Pacific)	38,378	10.5	39,386	10.9	102.6
Overseas subtotal	319,675	87.1	320,659	88.8	100.3
Total	366,866	100.0	361,168	100.0	98.4

In Japan, we experienced lower sales of hematology instruments and reagents, as well as immunochemistry reagents. As a result, sales in Japan fell 14.2% year on year, to ¥40,509 million, and the sales ratio decreased 1.7 percentage points, to 11.2%.

Overseas, sales of reagents in the hemostasis and immunochemistry fields decreased. However, instrument sales rose in the urinalysis and other fields. Accordingly, overseas sales rose 0.3%, to ¥320,659 million, and the overseas sales ratio increased 1.7 percentage points, to 88.8%.

Selling, general and administrative (SG&A) expenses totaled ¥120,206 million, up 9.3% year on year, due primarily to an increase in personnel associated with business expansion, as well as higher amortization expenses related to investments in digital infrastructure. R&D expenses came to ¥20,444 million, down 9.3%.

As a result, on a consolidated basis for the first nine months of the fiscal year ending March 31, 2026, net sales amounted to ¥361,168 million (down 1.6% year on year), operating profit was ¥48,657 million (down 27.7%), profit before tax was ¥47,471 million (down 23.2%), and profit attributable to owners of the parent totaled ¥33,694 million (down 20.9%).

Performance by segment

(1) Headquarters

In South Korea, hematology instruments grew, but in Japan sales of hematology instruments and reagents decreased, as did sales of immunochemistry reagents. In the medical robotics business, sales of maintenance services grew, but sales of instruments decreased. Consequently, sales fell 8.9% year on year, to ¥60,580 million.

On the profit front, in addition to the decline in sales, a worsening cost of sales ratio and an increase in SG&A expenses led to a segment profit (operating profit) of ¥19,043 million (down 55.1%).

(2) Americas RHQ

In North America, sales rose for hematology instruments and reagents, as well as for urinalysis instruments and maintenance services. In Central and South America, sales of urinalysis instruments and reagents increased. As a result, sales in the Americas were up 5.0% year on year, to ¥95,061 million.

On the profit front, higher sales and other factors pushed up segment profit (operating profit) 16.4% year on year, to ¥6,289 million.

(3) EMEA RHQ

In the hematology field, sales of instruments and reagents grew, mainly in the region's key countries. Sales of instruments in the urinalysis and other fields also increased, bolstering sales for the region by 11.7% year on year, to ¥111,082 million.

Higher sales and an improved cost of sales ratio pushed up segment profit (operating profit) 13.5% year on year, to ¥8,864 million.

(4) China RHQ

Operating in a difficult business environment affected by policies to curtail medical expenses, we experienced significant sales declines in hematology instruments and reagents, as well as hemostasis reagents. As a result, segment sales were ¥65,414 million, down 20.1% year on year.

Although lower SG&A expenses had a positive impact on profit, lower sales caused segment profit (operating profit) to fall 9.3% year on year, to ¥7,467 million.

(5) Asia Pacific RHQ

Reagent sales increased in the hemostasis and urinalysis fields. In the hematology field, sales of instruments and maintenance services decreased, while reagent sales grew. Accordingly, sales expanded by 1.7%, to ¥29,027 million.

Despite the higher sales, segment profit (operating profit) decreased 16.5%, to ¥4,649 million, as the cost of sales ratio deteriorated owing to such factors as depreciation on our new production site in India, which was completed in August 2024.

2) Financial conditions analysis

(1) Financial conditions

As of December 31, 2025, total assets amounted to ¥698,249 million, up ¥32,980 million from their level on March 31. Among major factors, cash and cash equivalents were down ¥13,809 million, whereas inventories increased by ¥17,555 million, property, plant and equipment by ¥14,632 million. Among non-current assets, trade and other receivables expanded ¥5,473 million.

Meanwhile, total liabilities decreased by ¥3,914 million from March 31, 2025, to ¥196,820 million. Key changes included a ¥6,647 million rise in non-current lease liabilities and ¥1,716 million higher contract liabilities. Meanwhile, income taxes payable declined by ¥8,591 million, and accrued bonuses by ¥4,516 million.

Total equity increased by ¥36,894 million from March 31, 2025, to ¥501,429 million. Among principal reasons, other components of equity increased ¥26,640 million and retained earnings increased ¥11,211 million. The equity attributable to owners of the parent to total assets rose 2.0 percentage points, from 69.7% as of March 31, 2025, to 71.7%.

(2) Cash flows

As of December 31, 2025, cash and cash equivalents amounted to ¥75,760 million, down ¥13,809 million from March 31, 2025.

Cash flows from various activities during the first nine months of the fiscal year are described in more detail below.

(Cash flows from operating activities)

Net cash provided by operating activities was ¥50,044 million, down ¥8,878 million from the first nine months of the preceding fiscal year. As principal factors, profit before tax provided ¥47,471 million (¥14,321 million less than in the corresponding period of the preceding fiscal year), depreciation and amortization provided ¥34,820 million (up ¥6,119 million), a decrease in trade receivables provided ¥13,342 million (up ¥4,306 million), an increase in inventories used ¥12,602 million (up ¥210 million), and income taxes paid used ¥26,457 million (up ¥1,562 million).

(Cash flows from investing activities)

Net cash used in investing activities was ¥37,560 million (up ¥3,414 million). Among major factors, purchases of property, plant and equipment used ¥22,191 million (up ¥4,493 million), and purchases of intangible assets used ¥13,549 million (down ¥2,513 million).

(Cash flows from financing activities)

Net cash used in financing activities was ¥32,705 million (up ¥10,184 million). This was mainly

due to dividends paid of ¥22,441 million (up ¥4,360 million), and repayments of lease liabilities of ¥8,925 million (up ¥1,232 million).

3) Consolidated financial forecast

For the Company's consolidated financial forecast for the full fiscal year, please refer to the Announcement Regarding Notice of Revision to the Full-Year Financial Forecast, announced today (February 12, 2026).

4) Operating risks

In the first nine months under review, no new operating risk emerged, and there were no material changes to the operating risks outlined in our financial report for the previous fiscal year.

5) Business and financial issues to be addressed

There are no significant changes to the descriptions of "Priority business and financial issues to be addressed" in "Part I: Corporate Information, Section 2: Business Overview, 1. Management Policy, Management Environment and Issues to be Addressed" in the financial report for the previous fiscal year.

6) Important management contracts, etc.

No conclusions of important management contracts or decisions regarding them were made during the first nine months under review.

2. Condensed quarterly consolidated financial statements and notes

1) Condensed quarterly consolidated statement of financial position

(Unit: Millions of yen)

	As of March 31, 2025	As of December 31, 2025
Assets		
Current assets		
Cash and cash equivalents	89,570	75,760
Trade and other receivables	163,007	161,705
Inventories	81,811	99,367
Other short-term financial assets	654	637
Income taxes receivable	1,246	4,929
Other current assets	28,531	30,879
Total current assets	364,821	373,280
Non-current assets		
Property, plant and equipment	130,211	144,843
Goodwill	14,205	15,592
Intangible assets	92,146	93,016
Investments accounted for using the equity method	339	200
Trade and other receivables	26,978	32,452
Other long-term financial assets	12,034	15,036
Asset for retirement benefits	0	55
Other non-current assets	6,880	6,925
Deferred tax assets	17,651	16,845
Total non-current assets	300,447	324,968
Total assets	665,268	698,249

(Unit: Millions of yen)

	As of March 31, 2025	As of December 31, 2025
Liabilities and equity		
Liabilities		
Current liabilities		
Trade and other payables	31,865	31,120
Lease liabilities	9,250	9,402
Other current financial liabilities	1,403	1,372
Income taxes payable	12,784	4,193
Provisions	1,164	1,183
Contract liabilities	18,098	19,815
Accrued expenses	22,355	22,733
Accrued bonuses	14,709	10,192
Other current liabilities	11,194	12,186
Total current liabilities	122,826	112,200
Non-current liabilities		
Long-term loans payable	32,359	31,850
Lease liabilities	23,126	29,774
Other non-current financial liabilities	56	41
Liability for retirement benefits	2,127	2,506
Provisions	1,054	1,286
Other non-current liabilities	11,608	12,212
Deferred tax liabilities	7,575	6,948
Total non-current liabilities	77,908	84,619
Total liabilities	200,734	196,820
Equity		
Equity attributable to owners of the parent		
Capital stock	14,887	14,898
Capital surplus	20,960	21,011
Retained earnings	402,820	414,032
Treasury stock	(12,318)	(13,165)
Other components of equity	37,425	64,066
Total equity attributable to owners of the parent	463,776	500,842
Non-controlling interests	758	586
Total equity	464,534	501,429
Total liabilities and equity	665,268	698,249

2) Condensed quarterly consolidated statement of income

(Unit: Millions of yen)

	Nine months ended December 31, 2024	Nine months ended December 31, 2025
Net sales	366,866	361,168
Cost of sales	168,056	173,537
Gross profit	198,809	187,631
Selling, general and administrative expenses	109,971	120,206
Research and development expenses	22,542	20,444
Other operating income	1,647	2,785
Other operating expenses	598	1,108
Operating profit	67,345	48,657
Financial income	760	711
Financial expenses	2,181	2,661
Share of profit (loss) of associates accounted for using the equity method	(1,727)	(1,249)
Foreign exchange gain (loss)	(2,404)	2,013
Profit before tax	61,792	47,471
Income taxes expenses	19,295	13,948
Profit	42,497	33,522

Profit attributable to

Owners of the parent	42,615	33,694
Non-controlling interests	(118)	(171)
Profit	42,497	33,522

(Unit: Yen)

Earnings per share

Basic	68.35	54.05
Diluted	68.33	54.05

3) Condensed quarterly consolidated statement of comprehensive income

(Unit: Millions of yen)

	Nine months ended December 31, 2024	Nine months ended December 31, 2025
Profit	42,497	33,522
Other comprehensive income		
Items that will not be reclassified subsequently to profit or loss		
Net gain (loss) on financial assets measured at fair value through other comprehensive income	(1,401)	958
Total	<hr/> (1,401)	<hr/> 958
Items that may be reclassified subsequently to profit or loss		
Exchange differences on translation of foreign operations	7,482	25,602
Share of other comprehensive income of investments accounted for using the equity method	8	37
Total	<hr/> 7,490	<hr/> 25,640
Total other comprehensive income	<hr/> 6,089	<hr/> 26,598
Comprehensive income	<hr/> 48,586	<hr/> 60,121
Comprehensive income attributable to		
Owners of the parent	48,705	60,292
Non-controlling interests	(118)	(171)
Comprehensive income	<hr/> 48,586	<hr/> 60,121

4) Condensed quarterly consolidated statement of changes in equity

Nine months ended December 31, 2024

(Unit: Millions of yen)

	Equity attributable to owners of the parent						Non-controlling interests	Total equity
	Capital stock	Capital surplus	Retained earnings	Treasury stock	Other components of equity	Total		
As of April 1, 2024	14,729	20,830	365,985	(12,315)	42,814	432,045	851	432,897
Profit	—	—	42,615	—	—	42,615	(118)	42,497
Other comprehensive income	—	—	—	—	6,089	6,089	—	6,089
Comprehensive income	—	—	42,615	—	6,089	48,705	(118)	48,586
Exercise of warrants	121	69	—	—	—	191	—	191
Share-based payment transactions	—	27	—	—	—	27	—	27
Cash dividends	—	—	(18,081)	—	—	(18,081)	—	(18,081)
Purchase of treasury stock	—	—	—	(2)	—	(2)	—	(2)
Disposal of treasury stock	—	0	—	0	—	0	—	0
Transfer to retained earnings	—	—	1,361	—	(1,361)	—	—	—
Total transactions with the owners	121	97	(16,720)	(2)	(1,361)	(17,864)	—	(17,864)
As of December 31, 2024	14,851	20,928	391,881	(12,318)	47,542	462,885	733	463,618

Nine months ended December 31, 2025

(Unit: Millions of yen)

	Equity attributable to owners of the parent						Non-controlling interests	Total equity
	Capital stock	Capital surplus	Retained earnings	Treasury stock	Other components of equity	Total		
As of April 1, 2025	14,887	20,960	402,820	(12,318)	37,425	463,776	758	464,534
Profit	—	—	33,694	—	—	33,694	(171)	33,522
Other comprehensive income	—	—	—	—	26,598	26,598	—	26,598
Comprehensive income	—	—	33,694	—	26,598	60,292	(171)	60,121
Exercise of warrants	10	6	—	—	—	16	—	16
Share-based payment transactions	—	75	—	—	—	75	—	75
Cash dividends	—	—	(22,441)	—	—	(22,441)	—	(22,441)
Purchase of treasury stock	—	—	—	(877)	—	(877)	—	(877)
Disposal of treasury stock	—	(31)	—	31	—	—	—	—
Transfer to retained earnings	—	—	(41)	—	41	—	—	—
Total transactions with the owners	10	50	(22,483)	(846)	41	(23,226)	—	(23,226)
As of December 31, 2025	14,898	21,011	414,032	(13,165)	64,066	500,842	586	501,429

5) Condensed quarterly consolidated statement of cash flows

(Unit: Millions of yen)

	Nine months ended December 31, 2024	Nine months ended December 31, 2025
Cash flows from operating activities		
Profit before tax	61,792	47,471
Depreciation and amortization	28,700	34,820
Share of loss (profit) of associates accounted for using the equity method	1,727	1,249
Loss on retirement of non-current assets	166	620
Decrease (increase) in trade receivable	9,036	13,342
Decrease (increase) in advance payments	458	(1,021)
Decrease (increase) in inventories	(12,391)	(12,602)
Increase (decrease) in trade payable	111	280
Increase (decrease) in accounts payable—other	(1,721)	(1,040)
Increase (decrease) in contract liabilities	865	511
Increase (decrease) in accrued expenses	681	(892)
Decrease/increase in consumption taxes receivable/payable	(741)	330
Increase (decrease) in accrued bonuses	(2,479)	(4,867)
Other—net	(1,579)	(569)
Subtotal	84,628	77,634
Interest and dividend received	474	471
Interest paid	(1,285)	(1,603)
Income taxes paid	(24,895)	(26,457)
Net cash provided by (used in) operating activities	58,922	50,044
Cash flows from investing activities		
Purchases of property, plant and equipment	(17,697)	(22,191)
Purchases of intangible assets	(16,063)	(13,549)
Payments resulting in an increase in long-term prepaid expenses	(626)	(758)
Purchases of investments in equity instruments	(2,008)	(254)
Proceeds from the sale of equity instruments	1,853	0
Purchase of investments in debt instruments	(399)	(978)
Payments into time deposits	(1,306)	(977)
Proceeds from withdrawal of time deposits	1,591	893
Other—net	510	255
Net cash provided by (used in) investing activities	(34,146)	(37,560)
Cash flows from financing activities		
Proceeds from long-term loans payable	3,500	—
Repayments of long-term loans payable	(435)	(508)
Exercise of warrants	191	16
Purchase of treasury shares	(2)	(877)
Dividends paid	(18,081)	(22,441)
Repayments of lease liabilities	(7,692)	(8,925)
Other—net	0	31
Net cash provided by (used in) financing activities	(22,520)	(32,705)
Effects of exchange rate changes on cash and cash equivalents	4,177	6,412
Net increase (decrease) in cash and cash equivalents	6,432	(13,809)
Cash and cash equivalents at the beginning of the term	75,507	89,570
Cash and cash equivalents at the end of the term	81,940	75,760

6) Notes to the condensed quarterly consolidated financial statements

1. Key considerations on the basis for the preparation of condensed quarterly consolidated financial statements

The condensed quarterly consolidated financial statements have been prepared in accordance with Article 5, Paragraph 2 of the Standards for Preparation of Quarterly Consolidated Financial Statements, etc. of Tokyo Stock Exchange, Inc. (However, in accordance with Article 5, Paragraph 5 of the Standards for the Preparation of Quarterly Financial Statements, some disclosures in International Accounting Standard No. 34 "Interim Financial Reporting" are omitted.)

2. Notes related to the going concern assumption

Not applicable

3. Segment information

1) Overview of reportable segments

The reportable segments of the Company and its subsidiaries (the Group) are the constituent business units of the Group for which separate financial data are available and that are examined on a regular basis for the purpose of enabling the Managing Board to allocate managerial resources and evaluate results of operations.

The Group is primarily engaged in the manufacture and sale of diagnostic instruments and reagents. These businesses are conducted in Japan and East Asia by Sysmex and in the Americas, EMEA, China, and the Asia Pacific by regional headquarters established therein. These companies formulate comprehensive strategies tailored to regional characteristics and conduct business activities accordingly. Some overseas subsidiaries are managed by Sysmex depending on the nature of their business.

The five managing company-specific segments are "Headquarters," "Americas RHQ," "EMEA RHQ," "China RHQ," and "AP RHQ."

The companies included in these reportable segments are outlined below.

Reportable segments	Companies included in the reportable segments
Headquarters	Sysmex Corporation, Sysmex RA Co., Ltd., 12 other domestic subsidiaries, Oxford Gene Technology IP Limited, Sysmex Partec GmbH, Sysmex Korea Co., Ltd., 12 other overseas subsidiaries
Americas RHQ	Sysmex America, Inc., Sysmex Reagents America, Inc., Sysmex do Brasil Industria e Comercio Ltda., five other subsidiaries in the Americas
EMEA RHQ	Sysmex Europe SE, Sysmex Deutschland GmbH, Sysmex UK Limited, Sysmex France S.A.S., 25 other subsidiaries in the EMEA region
China RHQ	Sysmex Shanghai Ltd., Jinan Sysmex Medical Electronics Co., Ltd., two other subsidiaries in China
AP RHQ	Sysmex Asia Pacific Pte Ltd., Sysmex India Pvt. Ltd., nine other subsidiaries in the Asia Pacific region

2) Segment profit and operating results

Profit and operating results from continuing operations by reportable segment of the Group are as follows:

Intersegment sales are determined based on market prices or costs of goods manufactured.

Accounting policies of reporting segments are consistent with the Group's accounting policies indicated in the consolidated financial statements for the previous fiscal year.

Nine months ended December 31, 2024

(Unit: Millions of yen)

	Reportable segment						Adjustments (Note 1)	Consolidated (Note 2)
	Head- quarters	Americas RHQ	EMEA RHQ	China RHQ	AP RHQ	Total		
Sales								
Sales to external customers	66,472	90,553	99,408	81,897	28,534	366,866	—	366,866
Intersegment sales	114,446	18	463	427	32	115,389	(115,389)	—
Total	180,918	90,572	99,872	82,325	28,567	482,255	(115,389)	366,866
Segment profit (loss)	42,445	5,405	7,807	8,234	5,569	69,462	(2,116)	67,345
Financial income	—	—	—	—	—	—	—	760
Financial expenses	—	—	—	—	—	—	—	2,181
Share of profit (loss) of associates accounted for using the equity method	—	—	—	—	—	—	—	(1,727)
Foreign exchange gain (loss)	—	—	—	—	—	—	—	(2,404)
Profit before tax	—	—	—	—	—	—	—	61,792
Income taxes expenses	—	—	—	—	—	—	—	19,295
Profit	—	—	—	—	—	—	—	42,497

Notes: 1. Segment profit (loss) adjustments of negative ¥2,116 million include negative ¥1,880 million for the unrealized gains on inventories and negative ¥236 million for the unrealized gains on non-current assets.

2. Segment profit (loss) is adjusted to coincide with operating profit in the condensed quarterly consolidated statement of income.

Nine months ended December 31, 2025

(Unit: Millions of yen)

	Reportable segment						Adjustments (Note 1)	Consolidated (Note 2)
	Head- quarters	Americas RHQ	EMEA RHQ	China RHQ	AP RHQ	Total		
Sales								
Sales to external customers	60,580	95,061	111,082	65,414	29,027	361,168	—	361,168
Intersegment sales	94,204	20	467	271	40	95,005	(95,005)	—
Total	154,785	95,082	111,550	65,686	29,068	456,173	(95,005)	361,168
Segment profit (loss)	19,043	6,289	8,864	7,467	4,649	46,314	2,342	48,657
Financial income	—	—	—	—	—	—	—	711
Financial expenses	—	—	—	—	—	—	—	2,661
Share of profit (loss) of associates accounted for using the equity method	—	—	—	—	—	—	—	(1,249)
Foreign exchange gain (loss)	—	—	—	—	—	—	—	2,013
Profit before tax	—	—	—	—	—	—	—	47,471
Income taxes expenses	—	—	—	—	—	—	—	13,948
Profit	—	—	—	—	—	—	—	33,522

Notes: 1. Segment profit (loss) adjustments of ¥2,342 million include ¥2,269 million for the unrealized gains on inventories and ¥72 million for the unrealized gains on non-current assets.

2. Segment profit (loss) is adjusted to coincide with operating profit in the condensed quarterly consolidated statement of income.